Business Update

Phoqus enters pharmacokinetic study in humans of modified release technology in GSK drug

Published in Lab Law Weekly, February 2nd, 2007

Phoqus Group plc (PQS), an oral drug delivery and development company, announced that a formulation it is developing for GlaxoSmithKline (GSK) has entered a pharmacokinetic study in human volunteers, following a successful feasibility study.

Phoqus has undertaken an early stage formulation development project for GSK using its proprietary modified release technology, Qtrol. The objectives of the pharmacokinetic study are to determine the release profile and bioavailability of the drug from the formulation.

GSK has financed the development of the formulation and manufacture of clinical supplies by Phoqus, and is conducting the pharmacokinetic study....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry